13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
59 檔
19.3%
At the close of Q3 2024, Exome Asset Management LLC disclosed equity holdings valued at approximately $162.1M, spread across 59 reported holdings.
During Q3 2024, Exome Asset Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.26% | +0.72% | +7.70% | |
| 2 | ASND | Ascendis Pharma A/S | Stock-Other | 4.43% | — | +119.25% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.63% | -1.75% | +167.40% | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.57% | — | — | |
| 5 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.28% | +5.59% | NEW | |
| 6 | ALGN | Align Technology Inc | Stock-Healthcare | 3.21% | — | — | |
| 7 | CI | THE Cigna Group | Stock-Healthcare | 2.86% | — | — | |
| 8 | GILD | Gilead Sciences Inc | Stock-Healthcare | 2.83% | — | — | |
| 9 | GERN | Geron CORP | Stock-Other | 2.78% | +0.49% | NEW | |
| 10 | BNTX | Biontech Se-adr | Stock-Other | 2.77% | — | — | |
| 11 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.73% | — | — | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.68% | — | — | |
| 13 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.47% | -0.32% | +16.81% | |
| 14 | ONC | Beone Medicines Ltd-adr | Stock-Other | 2.32% | — | -53.92% | |
| 15 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.29% | — | — | |
| 16 | GKOS | Glaukos CORP | Stock-Healthcare | 2.28% | +0.55% | — | |
| 17 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 2.18% | — | — | |
| 18 | IRON | Disc Medicine Inc | Stock-Other | 2.14% | — | +5.76% | |
| 19 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.09% | -0.38% | — | |
| 20 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.99% | -0.58% | — | |
| 21 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.98% | -0.88% | — | |
| 22 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.96% | -1.78% | EXIT | |
| 23 | RDY | Dr. Reddy's Laboratories-adr | Stock-Other | 1.95% | — | — | |
| 24 | NTRA | Natera Inc | Stock-Healthcare | 1.93% | +0.38% | +20.38% | |
| 25 | BIIB | Biogen Inc | Stock-Healthcare | 1.74% | — | — | |
| 26 | INSM | Insmed Inc | Stock-Healthcare | 1.66% | -1.34% | -40.85% | |
| 27 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.55% | — | — | |
| 28 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 29 | ETNBGBP | 89bio Inc | Stock-Other | 1.50% | — | — | |
| 30 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.50% | — | — | |
| 31 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.49% | — | -49.74% | |
| 32 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.47% | — | — | |
| 33 | AMGN | Amgen Inc | Stock-Healthcare | 1.46% | — | -43.22% | |
| 34 | GH | Guardant Health Inc | Stock-Healthcare | 1.39% | +2.30% | +13.67% | |
| 35 | NUVL | Nuvalent Inc-a | Stock-Other | 1.38% | — | — | |
| 36 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 1.22% | — | — | |
| 37 | KURA | Kura Oncology Inc | Stock-Other | 1.19% | — | -31.45% | |
| 38 | RZLT | Rezolute Inc | Stock-Other | 1.15% | — | +24.67% | |
| 39 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.13% | — | +20.65% | |
| 40 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.08% | — | — | |
| 41 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.03% | — | — | |
| 42 | STAA | Staar Surgical Co | Stock-Other | 1.02% | — | — | |
| 43 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.01% | — | — | |
| 44 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.01% | — | — | |
| 45 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.75% | — | — | |
| 46 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.74% | — | +12.21% | |
| 47 | ALVO | Alvotech | Stock-Other | 0.72% | — | -8.99% | |
| 48 | QTRX | Quanterix CORP | Stock-Other | 0.64% | — | +23.22% | |
| 49 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.63% | +0.31% | — | |
| 50 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.55% | — | — |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 59 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ASND, BBIO) accounted for 19.3% of total reported equity market value during Q3 2024.
During Q3 2024, Exome Asset Management LLC's top holdings by market value included LLY (6.3%)、ASND (4.4%)、BBIO (3.6%). The largest single position, LLY, represented 6.3% of total portfolio value.
In Q3 2024, Exome Asset Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.